Genmab A (GMAB) Free Cash Flow (2018 - 2026)

Genmab A has reported Free Cash Flow for 7 years, with the latest figure at $3.0 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 98.95% year-over-year to $3.0 million; the trailing twelve-month figure through Mar 2026 stood at $888.0 million (down 13.28% YoY), and the FY2025 full-year result was $1.1 billion, up 4.55% from the prior year.
• Free Cash Flow for Q1 2026 stood at $3.0 million, down from $536.0 million in the prior quarter.
• The five-year high for Free Cash Flow was $536.0 million in Q3 2025, with the low at -$4.6 billion in Q4 2023.
• Historically, Free Cash Flow has averaged -$313.2 million across 4 years, with a median of $293.0 million in 2024.
• Annual changes were most pronounced in 2025 — Free Cash Flow surged 79.26% — and 2026, when it slumped 98.95%.
• Genmab A's Free Cash Flow stood at -$4.6 billion in 2023, then soared by 106.45% to $299.0 million in 2024, then surged by 79.26% to $536.0 million in 2025, then plunged by 99.44% to $3.0 million in 2026.
• The last three Free Cash Flow figures came in at $3.0 million (Q1 2026), $536.0 million (Q3 2025), and $349.0 million (Q2 2025), per Business Quant data.